Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

I’m curious whether Whistleblower Aid’s caseload has changed since the inauguration—I could see you getting an influx of cases, but I could also see whistleblowers being less likely to come forward ...

The last painkiller OK’d by the FDA was Celebrex, a Cox-2 inhibitor, according to CNN. That category of nonsteroidal, anti-inflammatory drug works by targeting the body’s production of a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Haemoglobin content in reticulocytes (Ret-He) is a sensitive indicator for monitoring short term deteriorations in iron and vitamin availability for erythropoiesis. Reticulocyte maturation coincides ...

[31] XL-184 (BMS 907351, cabozantinib; Exelixis, South San Francisco, CA, USA) is an oral inhibitor of several TK receptors. The primary targets are VEGFR2, RET, c-KIT and MET, which is highly ...

Inhibition of RET by siRNA-mediated knockdown or treatment with the tyrosine kinase inhibitor selpercatinib impaired the growth of CDK4/6i- and fulvestrant-resistant cell lines and patient-derived ...